AXSM Quote, Financials, Valuation and Earnings

Gilead Sciences, Inc. has a net margin of -27.62% compared to Axsome Therapeutics, Inc.'s net margin of 39.21%. Axsome Therapeutics, Inc.'s return on equity of -327.97% beat Gilead Sciences, Inc.'s return on equity of 41.48%.

Axsome Therapeutics, Inc. has a consensus price target of $198.69, signalling upside risk potential of 17.31%. On the other hand Gilead Sciences, Inc. has an analysts' consensus of $134.22 which suggests that it could grow by 10.84%. Given that Axsome Therapeutics, Inc. has higher upside potential than Gilead Sciences, Inc., analysts believe Axsome Therapeutics, Inc. is more attractive than Gilead Sciences, Inc..

Axsome Therapeutics, Inc. has a beta of 0.438, which suggesting that the stock is 56.163% less volatile than S&P 500. In comparison Gilead Sciences, Inc. has a beta of 0.334, suggesting its less volatile than the S&P 500 by 66.568%.

Axsome Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences, Inc. offers a yield of 2.61% to investors and pays a quarterly dividend of $0.79 per share. Axsome Therapeutics, Inc. pays -- of its earnings as a dividend. Gilead Sciences, Inc. pays out 805.23% of its earnings as a dividend.

Axsome Therapeutics, Inc. quarterly revenues are $171M, which are smaller than Gilead Sciences, Inc. quarterly revenues of $7.8B. Axsome Therapeutics, Inc.'s net income of -$47.2M is lower than Gilead Sciences, Inc.'s net income of $3.1B. Notably, Axsome Therapeutics, Inc.'s price-to-earnings ratio is -- while Gilead Sciences, Inc.'s PE ratio is 18.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axsome Therapeutics, Inc. is 14.85x versus 5.24x for Gilead Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Innoviva, Inc. has a net margin of -27.62% compared to Axsome Therapeutics, Inc.'s net margin of 80.81%. Axsome Therapeutics, Inc.'s return on equity of -327.97% beat Innoviva, Inc.'s return on equity of 17.06%.

Axsome Therapeutics, Inc. has a consensus price target of $198.69, signalling upside risk potential of 17.31%. On the other hand Innoviva, Inc. has an analysts' consensus of $32.50 which suggests that it could grow by 65.99%. Given that Innoviva, Inc. has higher upside potential than Axsome Therapeutics, Inc., analysts believe Innoviva, Inc. is more attractive than Axsome Therapeutics, Inc..

Axsome Therapeutics, Inc. has a beta of 0.438, which suggesting that the stock is 56.163% less volatile than S&P 500. In comparison Innoviva, Inc. has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.652%.

Axsome Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Innoviva, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axsome Therapeutics, Inc. pays -- of its earnings as a dividend. Innoviva, Inc. pays out -- of its earnings as a dividend.

Axsome Therapeutics, Inc. quarterly revenues are $171M, which are larger than Innoviva, Inc. quarterly revenues of $111.3M. Axsome Therapeutics, Inc.'s net income of -$47.2M is lower than Innoviva, Inc.'s net income of $89.9M. Notably, Axsome Therapeutics, Inc.'s price-to-earnings ratio is -- while Innoviva, Inc.'s PE ratio is 14.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axsome Therapeutics, Inc. is 14.85x versus 3.85x for Innoviva, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Madrigal Pharmaceuticals, Inc. has a net margin of -27.62% compared to Axsome Therapeutics, Inc.'s net margin of -39.75%. Axsome Therapeutics, Inc.'s return on equity of -327.97% beat Madrigal Pharmaceuticals, Inc.'s return on equity of -40.56%.

Axsome Therapeutics, Inc. has a consensus price target of $198.69, signalling upside risk potential of 17.31%. On the other hand Madrigal Pharmaceuticals, Inc. has an analysts' consensus of $606.21 which suggests that it could grow by 17.93%. Given that Madrigal Pharmaceuticals, Inc. has higher upside potential than Axsome Therapeutics, Inc., analysts believe Madrigal Pharmaceuticals, Inc. is more attractive than Axsome Therapeutics, Inc..

Axsome Therapeutics, Inc. has a beta of 0.438, which suggesting that the stock is 56.163% less volatile than S&P 500. In comparison Madrigal Pharmaceuticals, Inc. has a beta of -1.001, suggesting its less volatile than the S&P 500 by 200.123%.

Axsome Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Madrigal Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axsome Therapeutics, Inc. pays -- of its earnings as a dividend. Madrigal Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Axsome Therapeutics, Inc. quarterly revenues are $171M, which are smaller than Madrigal Pharmaceuticals, Inc. quarterly revenues of $287.3M. Axsome Therapeutics, Inc.'s net income of -$47.2M is higher than Madrigal Pharmaceuticals, Inc.'s net income of -$114.2M. Notably, Axsome Therapeutics, Inc.'s price-to-earnings ratio is -- while Madrigal Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axsome Therapeutics, Inc. is 14.85x versus 15.39x for Madrigal Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vanda Pharmaceuticals, Inc. has a net margin of -27.62% compared to Axsome Therapeutics, Inc.'s net margin of -40.15%. Axsome Therapeutics, Inc.'s return on equity of -327.97% beat Vanda Pharmaceuticals, Inc.'s return on equity of -16.55%.

Axsome Therapeutics, Inc. has a consensus price target of $198.69, signalling upside risk potential of 17.31%. On the other hand Vanda Pharmaceuticals, Inc. has an analysts' consensus of $13.63 which suggests that it could grow by 85.63%. Given that Vanda Pharmaceuticals, Inc. has higher upside potential than Axsome Therapeutics, Inc., analysts believe Vanda Pharmaceuticals, Inc. is more attractive than Axsome Therapeutics, Inc..

Axsome Therapeutics, Inc. has a beta of 0.438, which suggesting that the stock is 56.163% less volatile than S&P 500. In comparison Vanda Pharmaceuticals, Inc. has a beta of 0.604, suggesting its less volatile than the S&P 500 by 39.647%.

Axsome Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axsome Therapeutics, Inc. pays -- of its earnings as a dividend. Vanda Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Axsome Therapeutics, Inc. quarterly revenues are $171M, which are larger than Vanda Pharmaceuticals, Inc. quarterly revenues of $56.3M. Axsome Therapeutics, Inc.'s net income of -$47.2M is lower than Vanda Pharmaceuticals, Inc.'s net income of -$22.6M. Notably, Axsome Therapeutics, Inc.'s price-to-earnings ratio is -- while Vanda Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axsome Therapeutics, Inc. is 14.85x versus 2.03x for Vanda Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.